CN109312364A - 用于感染树突状细胞的多模式载体 - Google Patents

用于感染树突状细胞的多模式载体 Download PDF

Info

Publication number
CN109312364A
CN109312364A CN201780017523.9A CN201780017523A CN109312364A CN 109312364 A CN109312364 A CN 109312364A CN 201780017523 A CN201780017523 A CN 201780017523A CN 109312364 A CN109312364 A CN 109312364A
Authority
CN
China
Prior art keywords
nucleic acid
recombinant nucleic
acid vector
virus
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780017523.9A
Other languages
English (en)
Chinese (zh)
Inventor
派翠克·松吉翁
卡伊万·尼亚兹
沙赫鲁兹·拉比扎德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valley Cell Co Ltd
Original Assignee
Valley Cell Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valley Cell Co Ltd filed Critical Valley Cell Co Ltd
Publication of CN109312364A publication Critical patent/CN109312364A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780017523.9A 2016-03-18 2017-03-20 用于感染树突状细胞的多模式载体 Pending CN109312364A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662310551P 2016-03-18 2016-03-18
US62/310,551 2016-03-18
US201662313596P 2016-03-25 2016-03-25
US62/313,596 2016-03-25
PCT/US2017/023117 WO2017161360A2 (en) 2016-03-18 2017-03-20 Multimodal vector for dendritic cell infection

Publications (1)

Publication Number Publication Date
CN109312364A true CN109312364A (zh) 2019-02-05

Family

ID=59850551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780017523.9A Pending CN109312364A (zh) 2016-03-18 2017-03-20 用于感染树突状细胞的多模式载体

Country Status (11)

Country Link
US (1) US20210198689A1 (enExample)
EP (1) EP3430148A4 (enExample)
JP (1) JP2019508044A (enExample)
KR (1) KR20180118198A (enExample)
CN (1) CN109312364A (enExample)
AU (1) AU2017233072B2 (enExample)
CA (1) CA3016389A1 (enExample)
IL (1) IL261812A (enExample)
MX (1) MX2018011306A (enExample)
SG (1) SG11201808058PA (enExample)
WO (1) WO2017161360A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201414021D0 (en) 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
CN108351917B (zh) 2015-08-25 2022-03-08 南托米克斯有限责任公司 用于高精度识别变体的系统和方法
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
EP3478312A4 (en) 2016-06-30 2020-07-29 Nant Holdings IP, LLC NANT CANCER VACCINE
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
JP2019532621A (ja) 2016-08-29 2019-11-14 サイオクサス セラピューティクス リミテッド 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス
LT3630143T (lt) 2017-06-01 2023-09-25 Akamis Bio Limited Onkolitinis virusas ir būdas
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085433A1 (en) * 2001-11-09 2005-04-21 Claudia Breidenstein Cellular vaccines comprising adjuvants
CN1761757A (zh) * 2003-01-07 2006-04-19 香港大学 用血管抑制素协同加强腺伴随病毒介导的b7.1免疫接种以根除扩散的肝转移性肿瘤
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
CN102533859A (zh) * 2012-01-12 2012-07-04 中国人民解放军第二军医大学 携带可诱导性共刺激分子基因的腺病毒载体及其构建方法与应用
CN103221544A (zh) * 2010-09-24 2013-07-24 昂克斯治疗有限公司 编码单克隆抗-ctla-4抗体的溶瘤腺病毒载体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4409097B2 (ja) * 1998-12-09 2010-02-03 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
JP4588296B2 (ja) * 2001-04-05 2010-11-24 ジョンズ・ホプキンス・ユニバーシティ キメラワクチン
JP2008535868A (ja) * 2005-04-14 2008-09-04 ザ ユニバーシティー オブ クイーンズランド 免疫調節組成物およびそのための使用
HUE037829T2 (hu) * 2011-08-31 2018-09-28 St Jude Childrens Res Hospital Eljárások és készítmények lizoszomális exocitózis aktivitás mértékének detektálására és alkamazási eljárások
EP3587455A1 (en) * 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
MY196581A (en) * 2013-11-01 2023-04-19 Pfizer Vectors for Expression of Prostate-Associated Antigens
KR102395820B1 (ko) * 2013-11-05 2022-05-09 버베리안 노딕 에이/에스 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
ES2963718T3 (es) * 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
NZ725459A (en) * 2014-05-13 2023-04-28 Bavarian Nordic As Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050085433A1 (en) * 2001-11-09 2005-04-21 Claudia Breidenstein Cellular vaccines comprising adjuvants
CN1761757A (zh) * 2003-01-07 2006-04-19 香港大学 用血管抑制素协同加强腺伴随病毒介导的b7.1免疫接种以根除扩散的肝转移性肿瘤
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
CN103221544A (zh) * 2010-09-24 2013-07-24 昂克斯治疗有限公司 编码单克隆抗-ctla-4抗体的溶瘤腺病毒载体
CN102533859A (zh) * 2012-01-12 2012-07-04 中国人民解放军第二军医大学 携带可诱导性共刺激分子基因的腺病毒载体及其构建方法与应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
余传霖等: "《现代医学免疫学》", 31 October 1998, 上海医科大学出版社 *
张克强等: "p53抗原肽及B7重组痘苗病毒抗肿瘤的研究", 《中国肿瘤生物治疗杂志》 *
牛天贵等: "《食品免疫学》", 30 September 2010, 中国农业大学出版社 *
罗明泉: "《实用临床免疫诊断学》", 31 July 2000, 海洋出版社 *
胡泽斌: "溶瘤腺病毒载体系统的构建及其功能研究", 《中国博士学位论文全文数据库》 *

Also Published As

Publication number Publication date
EP3430148A4 (en) 2020-01-01
CA3016389A1 (en) 2017-09-21
KR20180118198A (ko) 2018-10-30
IL261812A (en) 2018-10-31
AU2017233072B2 (en) 2020-12-24
WO2017161360A4 (en) 2017-11-16
JP2019508044A (ja) 2019-03-28
MX2018011306A (es) 2019-08-16
SG11201808058PA (en) 2018-10-30
WO2017161360A3 (en) 2017-10-26
EP3430148A2 (en) 2019-01-23
US20210198689A1 (en) 2021-07-01
AU2017233072A1 (en) 2018-09-13
WO2017161360A2 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
CN109312364A (zh) 用于感染树突状细胞的多模式载体
JP6970991B2 (ja) トランスポザーゼポリペプチド及びその使用
Weller et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond
CN109952309B (zh) 用于细胞治疗的组成型活性细胞因子受体
JP2021521776A (ja) Ｍａｇｅ−ｂ２特異性を有するｔ細胞受容体およびその使用
CN113286811A (zh) 改善过继性细胞疗法的效力和安全性
US12491201B2 (en) Maximizing T-cell memory and compositions and methods therefor
CN109563521A (zh) 用于新表位呈递的序列排列和序列
CN109789190A (zh) Nant癌症疫苗
CN115551537A (zh) 肿瘤细胞疫苗
US12247086B2 (en) Enhanced immunogenicity for GPI-anchored antigens
CN111433222A (zh) 用于免疫疗法的t细胞受体
CN109906086A (zh) 树突细胞的转染及其方法
CN109069598A (zh) 双靶向腺病毒皮下递送
Okano et al. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity
Tran et al. A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice
Danishmalik et al. Tumor regression is mediated via the induction of HER263-71-specific CD8+ CTL activity in a 4T1. 2/HER2 tumor model: no involvement of CD80 in tumor control
US20220133868A1 (en) Tumor cell vaccines
US20200109366A1 (en) Recombinant nk cells expressing co-stimulatory molecules
Neal et al. Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity
Omabe et al. HER2-specific vaccines for HER2-positive breast Cancer immunotherapy
Savage Cancer immunotherapy therapeutic manipulation of the CD8-HLA class I interaction: potential and challenges
CN121038798A (zh) Cd4+细胞毒性t细胞及其使用方法
HK40030417B (zh) 用於免疫疗法的t细胞受体
HK40030417A (en) T cell receptors for immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190205

WD01 Invention patent application deemed withdrawn after publication